Please assess the completion status of the following clinical trial:

Trial Title: Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 or over,~* Who had been included in the Transpeg 1 study,~* Non-responders after a three month peginterferon alfa-2a / ribavirin bitherapy or with a recurrent disease during the Transpeg 1 maintenance phase, whatever the randomization group (ribavirin or placebo),~* With a positive qualitative PCR at inclusion,~* With a METAVIR histologic score of 1 or more on the last biopsy (done within the 6 months preceding inclusion),~* Treated with tacrolimus for at least 6 months prior to inclusion,~* Having given a written informed consent.~Exclusion Criteria:~* Treatment with peginterferon or ribavirin within the 6 months preceding inclusion,~* Severe hepatocellular failure or decompensated cirrhosis,~* Acute graft rejection within the two months preceding inclusion, or signs of chronic rejection on the last biopsy, or retransplantation since inclusion in the Transpeg 1 study,~* Treatment with cyclosporin for more than 6 months during the 24 months preceding inclusion,~* Treatment with a mTOR inhibitor or with another investigational immunosuppressive drug,~* Positive serology for HIV or HBV,~* Cancer (or history of other malignancy during the last 5 years) except patients transplanted for hepatocellular carcinoma and basocellular or excised spinocellular carcinoma,~* Serious concomitant disease or acute or chronic disorder, other than the current transplant, treated with steroids,~* Serious cardiac pathology within the last 6 months,~* Women with ongoing pregnancy or breast-feeding,~* Serious chronic renal failure (creatinine clearance \< 30 ml/mn),~* Haemoglobin \< 10 g/dl, platelets \< 50 000/mm3 or neutrophils \< 1000 / mm3,~* Abnormal TSH values,~* Inability to cooperate or to communicate with the investigator,~* Contraindications to ribavirin, peginterferon alfa-2a or cyclosporin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciclosporin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).